| Nivolumab for patients with high-risk oral leukoplakia: A nonrandomized controlled trial GJ Hanna, A Villa, SP Nandi, R Shi, A ONeill, M Liu, CT Quinn, ... JAMA oncology 10 (1), 32-41, 2024 | 15 | 2024 |
| Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative … E Munzone, MM Regan, S Cinieri, E Montagna, L Orlando, R Shi, ... JAMA oncology 9 (9), 1267-1272, 2023 | 12 | 2023 |
| 650O A phase II study of nivolumab for high-risk oral leukoplakia GJ Hanna, A Villa, R Shi, A O'Neill, M Liu, CT Quinn, RK Curtin, M Flynn, ... Annals of Oncology 33, S839, 2022 | 9 | 2022 |
| 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first-or second-line treatment in … E Munzone, MM Regan, S Cinieri, E Montagna, L Orlando, R Shi, ... Annals of Oncology 33, S636-S637, 2022 | 7 | 2022 |
| Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). K Sehgal, R Shi, T Pappa, JK Min, LB Oakley, A ONeill, MJ Dennis, ... Journal of Clinical Oncology 42 (16_suppl), 6109-6109, 2024 | | 2024 |
| A window-of-opportunity (WOO) trial of giredestrant+/-LHRHa vs anastrozole+ LHRHa in premenopausal women with ER+/HER2-early breast cancer (EBC; IBCSG 67-22; PREcoopERA). E Munzone, R Shi, S Loi, M Colleoni, G Viale, V Bjelic-Radisic, A Perello, ... Journal of Clinical Oncology 42 (16_suppl), TPS628-TPS628, 2024 | | 2024 |
| Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma. GJ Hanna, LB Oakley, R Shi, A ONeill, KY Shin, K Sehgal, MJ Dennis, ... Journal of Clinical Oncology 42 (16_suppl), 6031-6031, 2024 | | 2024 |
| Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N)+ trastuzumab (H) alone or combined with avelumab (A)+/-utomilumab (U) in patients (pts) with … A Waks, R Shi, M Regan, C Dang, C Santa-Maria, K Westbrook, ... Cancer Research 84 (9_Supplement), RF02-06-RF02-06, 2024 | | 2024 |
| 157TiP A window-of-opportunity (WOO) trial of giredestrant+/-LHRHa vs anastrozole+ LHRHa in premenopausal women with ER+/HER2-early breast cancer (EBC)(IBCSG 67-22; PREcoopERA) E Munzone, R Shi, S Loi, MA Colleoni, G Viale, V Bjelic-Radisic, ... ESMO Open 9, 2024 | | 2024 |
